enGene Therapeutics Warrants
ENGNW
14 hedge funds and large institutions have $13.9M invested in enGene Therapeutics Warrants in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 5 closing their positions.
322% more capital invested
Capital invested by funds: $3.29M → $13.9M (+$10.6M)
2.56% more ownership
Funds ownership: 43.97% → 46.54% (+2.6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
18% less funds holding
Funds holding: 17 → 14 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$651K |
| 2 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$308K |
| 3 |
LP
LMR Partners
London,
United Kingdom
|
+$182K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$98.6K |
| 2 |
SCM
Saba Capital Management
New York
|
-$93.5K |
| 3 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$63.4K |
| 4 |
WA
Whitebox Advisors
Minneapolis,
Minnesota
|
-$22K |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$13.7K |
ENGNW Hedge Fund Activity: Q4 2025 in Review
14 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics Warrants (ENGNW) for Q4 2025, worth a combined $13.9M — up 322% from $3.29M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ENGNW and 2 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 1 added.
The largest buyer was Vivo Capital, opening a new position worth an estimated $651K. The largest seller was Wolverine Asset Management, cutting an estimated $98.6K.
- 14 institutional investors held enGene Therapeutics Warrants (ENGNW) as of Q4 2025, down from 17 in Q3 2025.
- Funds reported $13.9M of enGene Therapeutics Warrants stock for Q4 2025, up 322% quarter-over-quarter.
- 2 funds opened new enGene Therapeutics Warrants positions in Q4 2025 and 5 closed out, a net change of -3 holders.
- The largest enGene Therapeutics Warrants buyer in Q4 2025 was Vivo Capital, an estimated $651K added.
- The largest enGene Therapeutics Warrants seller in Q4 2025 was Wolverine Asset Management, an estimated $98.6K sold.
Based on aggregated 13F filings for Q4 2025.